Fred Lublin

64.8k total citations · 11 hit papers
241 papers, 37.1k citations indexed

About

Fred Lublin is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Fred Lublin has authored 241 papers receiving a total of 37.1k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Pathology and Forensic Medicine, 48 papers in Neurology and 47 papers in Rheumatology. Recurrent topics in Fred Lublin's work include Multiple Sclerosis Research Studies (178 papers), Peripheral Neuropathies and Disorders (40 papers) and Rheumatoid Arthritis Research and Therapies (29 papers). Fred Lublin is often cited by papers focused on Multiple Sclerosis Research Studies (178 papers), Peripheral Neuropathies and Disorders (40 papers) and Rheumatoid Arthritis Research and Therapies (29 papers). Fred Lublin collaborates with scholars based in United States, Canada and Switzerland. Fred Lublin's co-authors include Stephen C. Reingold, Chris H. Polman, Jerry S. Wolinsky, Alan J. Thompson, Magnhild Sandberg‐Wollheim, Paul O’Connor, Ludwig Kappos, Massimo Filippi, Brian G. Weinshenker and Eva Havrdová and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Fred Lublin

237 papers receiving 36.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

2011 7.6k citations Stephen C. Reingold, Ludwig Kappos et al. profile →
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

2001 5.4k citations Hans‐Peter Hartung, Fred Lublin et al. profile →
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

2005 4.0k citations Stephen C. Reingold, Hans‐Peter Hartung et al. profile →
New Multiple Sclerosis Phenotypic Classification

2014 3.7k citations Fred Lublin profile →
Defining the clinical course of multiple sclerosis

1996 2.9k citations Fred Lublin, Stephen C. Reingold Neurology profile →
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2006 2.4k citations Fred Lublin, Michael Panzara et al. profile →
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

2006 982 citations Richard A. Rudick, Peter A. Calabresi et al. profile →
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

2014 664 citations Peter A. Calabresi, Douglas S. Goodin et al. profile →
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]

2002 603 citations Douglas S. Goodin, Fred Lublin et al. Neurology profile →
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

2016 335 citations Fred Lublin, Jerry S. Wolinsky et al. profile →
How patients with multiple sclerosis acquire disability

2022 254 citations Fred Lublin, Dieter A. Häring et al. Brain profile →

Peers

Countries citing papers authored by Fred Lublin

Since Specialization

Citations

This map shows the geographic impact of Fred Lublin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Lublin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Lublin more than expected).

Fields of papers citing papers by Fred Lublin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Lublin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Lublin. The network helps show where Fred Lublin may publish in the future.

Co-authorship network of co-authors of Fred Lublin

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Lublin. A scholar is included among the top collaborators of Fred Lublin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Lublin. Fred Lublin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials 2025 ·Neurology ·Ludwig Kappos, (unknown), Frank Dahlke, Timothy Coetzee, Gary Cutter, (unknown), (unknown), Fred Lublin	0
2	Treating to target in multiple sclerosis: Do we know how to measure whether we hit it? 2024 ·European Journal of Neurology ·Gabriel Bsteh, Nik Krajnc, Patrick Altmann, Barry Hendin, (unknown), (unknown), Fred Lublin, Jiwon Oh, (unknown), Annemie Ribbens, (unknown), Dirk Smeets, Éric Thouvenot, (unknown), Thomas Berger	2
3	Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial 2023 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Gary Cutter, Richard A. Rudick, Carl de Moor, Carol M. Singh, Elizabeth Fisher, (unknown), Fred Lublin, Jerry S. Wolinsky, Henry F. McFarland, Steven Jacobson, Maria L. Naylor	7
4	Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community 2023 ·Multiple Sclerosis Journal ·Alan J. Thompson, Marcello Moccia, Maria Pia Amato, Peter A. Calabresi, Marcia Finlayson, Annie Hawton, Fred Lublin, Ruth Ann Marrie, Xavier Montalbán, Michael Panzara, Maria Pia Sormani, (unknown), Barbara G. Vickrey, Timothy Coetzee	4
5	Polygenicity of Comorbid Depression in Multiple Sclerosis 2023 ·Neurology ·Kaarina Kowalec, Kathryn C. Fitzgerald, Amber Salter, (unknown), Arvid Harder, Çharles N. Bernstein, James M. Bolton, Gary Cutter, Lesley A. Graff, Sara Hägg, Carol Hitchon, Yi Lu, Fred Lublin, Kyla A. McKay, Scott B. Patten, Amit Patki, Hemant K. Tiwari, Jerry S. Wolinsky, Ruth Ann Marrie	6
6	Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset 2023 ·Multiple Sclerosis Journal ·Marcus Koch, (unknown), Luís Brieva, Jop Mostert, Eva Strijbis, Jacynthe Comtois, Pavle Repovic, James D. Bowen, Jerry S. Wolinsky, Fred Lublin, Gary Cutter	6
7	The impact of relapse definition and measures of durability on MS clinical trial outcomes 2023 ·Multiple Sclerosis Journal ·(unknown), Gary Cutter, Stephen Krieger, Stacey S. Cofield, Jerry S. Wolinsky, Fred Lublin	7
8	How patients with multiple sclerosis acquire disability breakdown → 2022 ·Brain ·Fred Lublin, Dieter A. Häring, Habib Ganjgahi, Alex Ocampo, (unknown), Jelena Čuklina, (unknown), Frank Dahlke, Douglas L. Arnold, Heinz Wiendl, Tanuja Chitnis, Thomas E. Nichols, Bernd C. Kieseier, Robert A Bermel	254
9	Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis 2022 ·Neurology Neuroimmunology & Neuroinflammation ·Eleni S. Vasileiou, (unknown), Çharles N. Bernstein, Fred Lublin, Jerry S. Wolinsky, Gary Cutter, Elias S. Sotirchos, Kaarina Kowalec, Amber Salter, Shiv Saidha, Ellen M. Mowry, Peter A. Calabresi, Ruth Ann Marrie, Kathryn C. Fitzgerald	4
10	Cerebellar pathology and disability worsening in relapsing‐remitting multiple sclerosis: A retrospective analysis from the CombiRx trial 2021 ·European Journal of Neurology ·Maria Petracca, Gary Cutter, Sirio Cocozza, Léorah Freeman, (unknown), Monica Margoni, (unknown), Stephen Krieger, Mohamed Mounir El Mendili, Amgad Droby, Jerry S. Wolinsky, Fred Lublin, Matilde Inglese	4
11	Detection of subtle gait disturbance and future fall risk in early multiple sclerosis 2020 ·Neurology ·Rachel Brandstadter, (unknown), Stephen Krieger, Noam Y. Harel, Miguel X. Escalón, Ilana Katz Sand, Victoria M. Leavitt, Michelle Fabian, Korhan Buyukturkoglu, Sylvia Klineova, Claire Riley, Fred Lublin, Aaron Miller, James Sumowski	35
12	Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI 2019 ·Radiology ·Ponnada A. Narayana, Ivan Coronado, Sheeba J. Sujit, Jerry S. Wolinsky, Fred Lublin, Refaat E. Gabr	80
13	Outcomes in Patients with Progressive MS: Analysis of Teriflunomide Long-Term Extension Data (P3.038) 2016 ·Neurology ·Flavia Nelson, Christine Lebrun‐Frénay, William Camu, (unknown), Karthinathan Thangavelu, (unknown), (unknown), Philippe Truffinet, Jinjun Liang, Fred Lublin	2
14	Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002) 2016 ·Neurology ·Douglas L. Arnold, Amit Bar‐Or, Giancarlo Comi, Hans‐Peter Hartung, Stephen L. Hauser, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Gaëlle Klingelschmitt, Donna Masterman, Paulo Fontoura, Peter Chin, Hideki Garren, Jerry S. Wolinsky	1
15	Long-Term Follow-Up of Laquinimod 0.6 mg in Patients with Relapsing-Remitting Multiple Sclerosis 2 (P3.087) 2016 ·Neurology ·Cristoforo Comi, Timothy R. Vollmer, Fred Lublin, (unknown), Tali Gorfine, Mat D. Davis, Per Soelberg Sørensen, Volker Knappertz	1
16	Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201) 2015 ·Neurology ·Stephen L. Hauser, Gıancarlo Comı, Hans‐Peter Hartung, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Amit Bar‐Or, Douglas L. Arnold, Gaëlle Klingelschmitt, David Leppert, Algirdas Kakarieka, Hideki Garren, Ludwig Kappos	3
17	Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102) 2013 ·Neurology ·Douglas S. Goodin, Douglas Jeffery, Ludwig Kappos, Fred Lublin, Ernst‐Wilhelm Radue, Kottil Rammohan, Anthony T. Reder, Timothy Vollmer, Mark Agius, Tracy Stites, Bingbing Li, Linda Cappiello, Philipp von Rosenstiel, Peter A. Calabresi	4
18	Defining the clinical course of multiple sclerosis breakdown → 1996 ·Neurology ·Fred Lublin, Stephen C. Reingold	2920
19	Management of patients receiving interferon beta-1b for multiple sclerosis 1996 ·Neurology ·Fred Lublin, John N. Whitaker, Benjamin H. Eidelman, Aaron E. Miller, B. G. W. Arnason, J. S. Burks	125
20	Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up 1993 ·Journal of Interferon Research ·Robert L. Knobler, Jeffrey I. Greenstein, K. P. Johnson, Fred Lublin, Hillel Panitch, (unknown), (unknown), Joseph Muldoon, S. Marcus, Joy Wallenberg, (unknown), (unknown)	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact